Royalty Pharma plc financial data

Symbol
RPRX on Nasdaq
Location
110 East 59 Th Street, New York, NY
State of incorporation
United Kingdom
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 274 % -17.7%
Return On Equity 8.54 % -26.1%
Return On Assets 4.9 % -28.2%
Operating Margin 57.1 % -9.91%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 13.1B USD -4.38%
Weighted Average Number of Shares Outstanding, Basic 448M shares +0.13%
Weighted Average Number of Shares Outstanding, Diluted 594M shares -1.46%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.26B USD -3.86%
Research and Development Expense 2M USD -96.2%
General and Administrative Expense 237M USD -5.24%
Costs and Expenses 971M USD +12.6%
Operating Income (Loss) 1.29B USD -13.4%
Nonoperating Income (Expense) 38.4M USD -81.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 1.33B USD -21.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent 859M USD -24.3%
Earnings Per Share, Basic 1.92 USD/shares -24.4%
Earnings Per Share, Diluted 1.91 USD/shares -24.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 929M USD +94.8%
Other Assets, Current 4.19M USD -76.8%
Assets, Current 1.8B USD +41.4%
Other Assets, Noncurrent 33.5M USD +414%
Assets 18.2B USD +11.2%
Liabilities, Current 1.25B USD +677%
Other Liabilities, Noncurrent 12.1M USD +1242%
Liabilities 7.88B USD +25.1%
Retained Earnings (Accumulated Deficit) 2.85B USD +13%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 10.3B USD +2.56%
Liabilities and Equity 18.2B USD +11.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 665M USD -35.7%
Net Cash Provided by (Used in) Financing Activities -212M USD -0.77%
Net Cash Provided by (Used in) Investing Activities -86.7M USD +84.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 366M USD +38.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 929M USD +94.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 79M USD -4.38%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 1.13B USD +4401%
Additional Paid in Capital 4.1B USD +2.3%
Amortization of Intangible Assets 0 USD -100%
Interest Expense 184M USD -1.8%